santa cruz biotechnology, inc.
SCBT Logo

Welcome!        Items in Cart     Quick Order

A33 (M-319) Antibody: sc-50523

 |  Datasheet
  • rabbit polyclonal IgG, 200µg/ml
  • epitope corresponding to amino acids 1-319 representing full length A33 of mouse origin
  • recommended for detection of glycoprotein A33 of mouse and rat origin by WB, IP, IF and ELISA
 
Additional A33 Antibodies ...
 
Ordering Information
Recommended Support Products:
(click button of application of choice)
WB   IP   IF   siRNA  
 
Species Gene Name Gene ID Chromosome Location Isoform (mRNA) Accession # Protein Accession # OMIM™ Number
Mouse Gpa33 59290 1 H2.3 Q9JKA5
N/A
 
Set Currency

 Ordering Information
Product NameCatalog #UnitPriceQtyAddFavorites
A33 (M-319) sc-50523 200 µg/ml $279
 siRNA Gene Silencers (click product name for more information)
Product NameCatalog #UnitPriceQtyAddFavorites
A33 siRNA (m) sc-44822 10 µM $258
A33 siRNA (m)-PR sc-44822-PR 10 µM $23
 shRNA Plasmids (click product name for more information)
Product NameCatalog #UnitPriceQtyAddFavorites
A33 shRNA Plasmid (m) sc-44822-SH 20 µg $520
 shRNA Lentiviral Particles (click product name for more information)
Product NameCatalog #UnitPriceQtyAddFavorites
A33 siRNA shRNA (m) Lentiviral Particles sc-44822-V 200 µl $625

A33 Background Information
The A33 antigen is a transmembrane protein expressed almost exclusively in intestinal epithelium and in 95% of human colon cancers. Specifically, expression of the A33 protein occurs on the basolateral surfaces of intestinal epithelial cells of all lineages. The A33 antigen comprises an extracellular domain with two immunoglobulin-like domains, a single-span transmembrane domain, and a highly acidic cytoplasmic domain. Expression of A33 appears to be regulated by the intestine-specific homeobox transcription factor CDX1 and the gut-enriched Kruppel-like factor (GKLF). GKLF binds to the promoter region of the A33 gene in colon cancer cells, and mutations in the GKLF binding sequence leads to reduced expression of the A33 antigen. The therapeutic potential of administering the humanized monoclonal antibody A33 to colon cancer patients has proved encouraging.